 pharmacology intravenous oral etoposide epipodophyllotoxin derivative etoposide widespread use combination chemotherapy past decade phase-specific cytotoxicity last phases cell cycle mode action certain breaks DNA interaction DNA-topoisomerase II formation free radicals studies biexponential decay intravenous IV administration etoposide administered etoposide present urine Etoposide available oral IV preparations schedule-dependent once-daily doses days days results superior intermittent administration bioavailability oral etoposide absorption linear dose mg/d bioavailability decreases Factors bioavailability oral etoposide patient status concurrent medications hepatic renal function nausea vomiting numerous clinical trials etoposide excellent activity range tumors small cell lung cancer SCLC malignant lymphomas gestational trophoblastic tumors Ewing soft tissue sarcomas germ cell tumors modest activity tumors non-SCLC comparative studies available data oral daily days similar IV preparation range activity study elderly patients SCLC etoposide mg/d times response rate median survival months results similar intensive IV regimens Several studies chronic oral etoposide times Responses SCLC germ cell tumors patients standard etoposide-containing regimens data etoposide new drug schedule high response rates oral etoposide oral administration IV administration substitution flexibility chemotherapeutic administration hospitalization acceptable toxicity